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UK; 3Health Economics Research Group, Brunel University, London, UKA B S T R A C TBackground: The value of evidence about the performance of a
technology and the value of access to a technology are central to
policy decisions regarding coverage with, without, or only in research
and managed entry (or risk-sharing) agreements. Objectives: We aim
to outline the key principles of what assessments are needed to
inform “only in research” (OIR) or “approval with research” (AWR)
recommendations, in addition to approval or rejection. Methods: We
developed a comprehensive algorithm to inform the sequence of
assessments and judgments that lead to different types of guidance:
OIR, AWR, Approve, or Reject. This algorithm identiﬁes the order in
which assessments might be made, how similar guidance might be
arrived at through different combinations of considerations, and
when guidance might change. Results: The key principles are
whether the technology is expected to be cost-effective; whether the
technology has signiﬁcant irrecoverable costs; whether additional
research is needed; whether research is possible with approval and
whether there are opportunity costs that once committed by approvalee front matter Copyright & 2016, International S
r Inc. This is an open access article under the CC
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ndence to: Claire Rothery, Centre for Health Econocannot be recovered; and whether there are effective price reductions.
Determining expected cost-effectiveness is only a ﬁrst step. In
addition to AWR for technologies expected to be cost-effective and
OIR for those not expected to be cost-effective, there are other
important circumstances when OIR should be considered. Conclu-
sions: These principles demonstrate that cost-effectiveness is a
necessary but not sufﬁcient condition for approval. Even when
research is possible with approval, OIR may be appropriate when a
technology is expected to be cost-effective due to signiﬁcant
irrecoverable costs.
Keywords: cost-effectiveness, coverage with evidence development,
health technology assessment, only in research.
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The value of evidence about the performance of a technology and
the value of access to a technology are central to policy decisions
regarding coverage with, without, or only in research and managed
entry (or risk-sharing) agreements. Decisions about health technol-
ogies are increasingly being made close to license when the
evidence base to support the technology is least mature. This is
partly linked to changes in the regulatory landscape in which
regulators and payers have produced new approaches in an effort
to provide patients with timely access to new medicines. For
example, the European Medicines Agency has introduced the
“Adaptive Pathways” approach that is open to interventions in the
early stages of development [1,2]. Inevitably, this means that cover-
age decisions in many different jurisdictions and health caresystems are being made when there may be substantial uncertainty
surrounding the technology’s effectiveness, cost-effectiveness, and
potential for harm. In these circumstances, further evidence may be
particularly valuable because it can lead to better decisions that
improve patient outcomes and/or reduce resource costs. Establish-
ing the key principles for “only in research” (OIR), deﬁned as when a
technology is approved only within the context of a suitable
research study, and “approval with research” (AWR), which refers
to approval while research is being conducted, will enable coverage
decisions to be addressed in an explicit and transparent manner.
This has wide relevance to different types of health care systems,
helping to inform the questions posed by coverage with evidence
development and managed entry agreements [3–6].
If the resources available for health care are limited, then
approving a more costly technology will displace other activitiesociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 8 8 5 – 8 9 1886that would have otherwise generated improvements in health for
other patients [7]. If the objective of a health care system is to
improve health outcomes across the population it serves, then
even if a technology is expected to be more effective, the health
gained must be compared with the health expected to be forgone
elsewhere as a consequence of additional costs; that is, a cost-
effective technology will offer positive net health effects (NHEs) [8–
10]. An assessment of expected cost-effectiveness or NHEs relies
on evidence about effectiveness, impact on long-term overall
health and potential harms, as well as additional health care
costs together with some assessment of what health is likely to
be forgone as a consequence (the cost-effectiveness threshold)
[11]. In health systems without administrative budgets, there are
often constrains on the growth in health care expenditure. Even
where there are no constraints, the same principles are likely to
apply but the opportunity costs may manifest in terms of non-
health expenditure, for example, through increased insurance
premiums, co-payments, or taxation.
Such assessments are inevitably uncertain and without sufﬁ-
cient and good quality evidence, subsequent decisions about the use
of technologies will also be uncertain. There will be a chance that
the resources committed by the approval of a new technology may
be wasted if the expected positive NHEs are not realized. Equally,
rejecting a new technology will risk failing to provide access to a
valuable intervention if the NHEs prove to be greater than expected.
Therefore, if the social objective is to improve the overall health for
both current and future patients, then the need for and value of
additional evidence is an important consideration when making
decisions about the use of technologies [12–14]. This is even more
critical once it is recognized that the approval of a technology for
widespread use might reduce the prospects of conducting the type
of research that would provide the evidence needed [15]. In these
circumstances, there will be a trade-off between the NHEs to current
patients from early access to a cost-effective technology and the
health beneﬁts to future patients from withholding approval until
valuable research has been conducted [16].
Research also consumes valuable resources that could have
been devoted to patient care or to other more valuable research
priorities. Uncertain events in the near or distant future may also
change the value of the technology and the need for evidence
[17]. In addition, implementing a decision to approve a new
technology may commit resources that cannot subsequently be
recovered if guidance changes in the future [18–22]. Guidance
about the use of health technologies will depend on whether the
beneﬁts of research are likely to exceed the costs and whether
any beneﬁts of early approval are greater than withholding
approval until additional research is conducted or other sources
of uncertainty are resolved.
The purpose of this article was to outline the key principles of
what assessments are needed to inform coverage decisions. The
starting point is an assessment of expected cost-effectiveness
from an underlying extra-welfarist approach, which identiﬁes
improvements in health as an important objective of health care
provision [23]. This is the approach that has been adopted by
major decision-making bodies such as the National Institute for
Health and Care Excellence in the United Kingdom, the Pharma-
ceutical Beneﬁts Advisory Committee in Australia, and the
Canadian Agency for Drugs and Technologies in Health. These
principles do not presuppose how the assessments might be
informed in terms of the methods of analysis or how different
aspects of health gained and forgone might be measured and
valued. This distinction between principles and methods of
analysis is important because different health care systems (or
decision-making bodies) are likely to vary in terms of the social
values they apply as well as the time and resources available to
carry out an appraisal of a health technology and may adopt
different methods of analysis to inform the same question. Onthe basis of these principles, we present a comprehensive
algorithm that demonstrates how the sequence of assessments
and judgments can lead to different types of guidance: OIR, AWR,
Approve (without research), or Reject (without research). Full
details on the development of this comprehensive framework
and algorithm have been described elsewhere [24], and we refer
the reader to this fuller description for a deeper insight. An
illustration of how the assessments can be informed in terms of
the methods of analysis is also presented elsewhere, with
application to a number of case studies [24,25].Key Principles and Assessments Needed
The key principles fall into a number of broad areas: 1) whether
the technology is expected to be cost-effective; 2) whether the
technology has signiﬁcant irrecoverable costs; 3) whether addi-
tional evidence/research is needed; 4) whether research is possi-
ble with approval and whether there are signiﬁcant (opportunity)
costs that once committed by approval cannot be recovered; and
5) whether there are any effective price reductions offered. These
key principles can be represented by a sequence of assessments
and judgments, which are summarized as a seven-point checklist
[24,25]:1. Is the technology expected to be cost-effective?
2. Are there signiﬁcant irrecoverable costs?
3. Does more research seem worthwhile?
4. Is the research possible with (without) approval?
5. Will other sources of uncertainty resolve over time?
6. Are the beneﬁts of research greater than the costs?
7. Are the beneﬁts of approval greater than the opportunity costs?
Based on estimates of expected NHE at each point of this
checklist, a judgment Yes or No can be made. For example, a
judgment at point 1 uses standard cost-effectiveness analysis to
estimate the NHE, a judgment at point 2 assesses the impact of
irrecoverable costs on NHE, and a judgment at points 3 and 4 uses
probabilistic sensitivity analysis and methods of value of infor-
mation analysis (the reader is referred to McKenna et al. [25] for
the methods of analysis for each point of the checklist). Guidance
will depend on the combined effect of these assessments. In
some cases, all seven assessments may not be necessary as
earlier decisions lead directly to guidance.
Figures 1 to 3 show the sequence of assessments and decisions
that lead to a particular category and type of guidance, represented
as a comprehensive algorithm. Four broad categories of guidance
are represented within the algorithm: Approve, AWR, OIR, and
Reject. Each different type of guidance illustrates how similar
guidance might be arrived at in different ways, helping to identify
the particular combination of considerations that underpin the
guidance. Figure 1 is for technologies without signiﬁcant irrecover-
able costs, whereas Figures 2 and 3 are for technologies with
signiﬁcant irrecoverable costs. Figures 2 and 3 are separated further
on the basis of whether the technology is expected to be cost-
effective and research is needed (Fig. 2) or whether it is not expected
to be cost-effective and research may or may not be needed (Fig. 3).
The key principles underpinning each of these assessments are
now described in the sections that follow. The reader is referred to
Claxton et al. [24] for a more detailed explanation.
Technologies Without Signiﬁcant Irrecoverable Costs
Although some element of cost which once committed cannot be
subsequently recovered is almost always present in the evalua-
tion of technologies, the sequence of assessments and decisions
for these technologies is relatively straightforward compared
Fig. 1 – An algorithm for OIR and AWR decisions—technologies without signiﬁcant irrecoverable costs. AWR, approval with
research; OIR, only in research.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 8 8 5 – 8 9 1 887with other technologies judged to have “signiﬁcant” irrecoverable
costs associated with approval. Signiﬁcant irrecoverable costs
depend on the commitment of upfront costs and whether there is
sufﬁcient ﬂexibility in when a patient can initiate treatment (e.g.,
if treatment can be delayed until uncertainty is resolved, then the
commitment of these irrecoverable costs can be avoided). Tech-
nologies without signiﬁcant irrecoverable costs are considered
ﬁrst as the simpler case (see Fig. 1).
Technologies expected to be cost-effective
The sequence of assessment is assumed to start with cost-
effectiveness and expected incremental NHE for the technology
relative to its comparators because this is the starting point used
by many decision-making bodies such as the National Institute for
Health and Care Excellence, the Pharmaceutical Beneﬁts Advisory
Committee, and the Canadian Agency for Drugs and Technologies in
Health. To avoid binary decisions of Approve or Reject under
conditions of uncertainty, the need for additional evidence should
be assessed. An assessment is also required of whether the research
needed to provide this evidence is possible if the technology is
approved for widespread use while the research is being conducted.
Need for evidence. Some initial assessment about whether
further research might be potentially worthwhile is important
because a “No” at this point can avoid further assessments; for
example, a technology offering substantial and well-evidenced
health beneﬁts at modest additional cost is likely to exhibit little
uncertainty about whether the expected population NHE is
positive. In these circumstances, further research may not beworthwhile, so guidance to approve could be issued (e.g.,
Approve4 in Fig. 1). If additional evidence is needed and further
research might be worthwhile, then further assessments and
decisions are required before guidance can be issued. Critically,
some assessment is required of the type of evidence that is
needed and whether or not the type of research required to
provide it is likely to be conducted if approval is granted [24,26].
Where research is possible with approval. If research is possible
with approval, some assessment of the long-term beneﬁts of
research is required, including 1) the likelihood that the type of
research needed will be conducted; 2) how long the results of
research will take to report; and 3) how much of the uncertainty
might be resolved by the research [15]. An assessment of other
sources of uncertainty that will resolve only over time is also needed,
for example, changes in prices or the launch of new technologies
[17]. These sources of uncertainty will inﬂuence the future beneﬁts of
research. For example, if the price of the technology is likely to fall
signiﬁcantly before or shortly after research reports, then the
beneﬁts, once the research reports, might be very limited. In these
circumstances, it might be better to approve (rather than AWR) and
reconsider whether and what type of research is needed at a later
date once these uncertainties have resolved. The judgment of
whether the long-term beneﬁts of research are likely to exceed its
expected costs determines guidance, with AWR1 and Approve1 in
Figure 1 dependent on “Yes” and “No,” respectively.
Where research is not possible with approval. The type of
research needed may not be possible once a technology is
Fig. 2 – An algorithm for OIR and AWR decisions—technologies with signiﬁcant irrecoverable costs, expected to be cost-
effective and research is needed. AWR, approval with research; OIR, only in research.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 8 8 5 – 8 9 1888approved for widespread use; for example, randomized clinical
trials may not be possible due to ethical concerns, recruitment
problems, and limited incentives for manufacturers. In these
circumstances, the expected beneﬁts of approval to current
patients must be balanced against the beneﬁts to future patients
from withholding approval until the research is conducted. The
same assessments of the long-term value of research and the
impact of other sources of uncertainty are still required. If the
beneﬁts of research are judged to be less than the costs (i.e.,
research is not worthwhile anyway), the technology can be
approved on the basis of current evidence and prices (Approve3
in Fig. 1). However, judging that research is worthwhile at this
point is not sufﬁcient for OIR guidance. An assessment of
whether the beneﬁts of early approval are expected to be greater
than the opportunity costs of research that may be forgone to
future patients is required. If the expected beneﬁts are judged to
be less than the opportunity costs, then OIR guidance would be
appropriate (OIR1 in Fig. 1), whereas if they are judged to be
greater, then approval would be appropriate (Approve2 in Fig. 1).Technologies not expected to be cost-effective
A technology that is not expected to be cost-effective based on
existing evidence is expected to impose negative NHE if it is
approved. In these circumstances, Approve can be ruled out, but
depending on the level of uncertainty in the current evidence and
other changes that may occur, subsequent assessments and
decisions are required before guidance is reached (see Fig. 1).Need for evidence. Even if the technology is not expected to be
cost-effective, the assessment may be uncertain; therefore, it
remains a possibility that the technology might offer positive
NHE. Again, the scale and consequences of uncertainty must be
considered and whether additional research might potentially be
worthwhile. If it is not, then the technology can be rejected
(Reject4 in Fig. 1). Alternatively, if further research might be
worthwhile, then an additional assessment is required of
whether the type of evidence and research that is needed can
be conducted without approval.
Where research is possible without approval. Generally, most
types of research (including randomized clinical trials) will be
possible without approval. The long-term value of research and
the impact of other sources of uncertainty are required. If,
following this reassessment, the expected beneﬁts of research
are judged to exceed the associated costs, then OIR would be
appropriate (OIR2 in Fig. 1). Alternatively, if the costs of research
are likely to exceed the longer term expected beneﬁts, then the
technology should be rejected at this point (Reject1 in Fig. 1).
Where research is not possible without approval. In some
circumstances it is possible that certain types of evidence might
be acquired only once a technology is in widespread use, for
example, linking surrogates to longer term outcomes, longer term
(or rare) adverse events, learning and incremental improvements,
or identifying particular types of patients who might beneﬁt most
[27]. Where the type of research needed is not possible (or is
Fig. 3 – An algorithm for OIR and AIR decisions—technologies with signiﬁcant irrecoverable costs, not expected to be cost-
effective and research is not needed. AWR, approval with research; OIR, only in research.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 8 8 5 – 8 9 1 889signiﬁcantly more costly) without approval, the same assessment
of the longer term beneﬁts of research is required. If further
research is judged not to be worthwhile following this reassess-
ment, the technology can be rejected (Reject2 in Fig. 1). Alter-
natively, if research is judged worthwhile, an additional
assessment of whether the beneﬁts of approval exceed the costs
is required. In this case, approval will impose opportunity costs
(negative expected NHE of widespread use of a cost-ineffective
technology). The key question is whether the net beneﬁts of the
research exceed these opportunity costs. If they don’t, then the
technology should be rejected even though research would have
been worthwhile (Reject3 in Fig. 1). Alternatively, if the net
beneﬁts of research more than offset the opportunity costs, then
AWR would be appropriate even though the technology is
expected to be cost-ineffective (AWR2 in Fig. 1).
Therefore, AWR guidance for technologies not expected to be
cost-effective is certainly possible but appropriate only in certain
circumstances, where 1) the type of research needed is not
possible without approval; 2) the long-term beneﬁts of the
research are likely to exceed the expected costs; and 3) the
additional net beneﬁts of such research exceed the opportunity
costs of approving a cost-ineffective technology.
Technologies with Signiﬁcant Irrecoverable Costs
Irrecoverable costs are those that once committed cannot be recov-
ered if guidance is changed at a later date. Irrecoverable costs are
most commonly thought of as “upfront” or capital costs of new
facilities or equipment with long life expectancy. In most appraisals,these types of cost are ﬁrst annuitized and then allocated pro rata to
the number of patients likely to be treated during the lifetime of the
equipment. If guidance remains unchanged throughout this period
(i.e., research does not report or other sources of uncertainty resolve),
then this common assumption has no inﬂuence. However, should
guidance change (initial approval is withdrawn) before the end of the
lifetime of the equipment, then, although future patents will no
longer use the technology, the cost of the equipment that was
allocated to them cannot be recovered.
Even in the absence of capital investment costs, most new
technologies impose initial per patient treatment costs that
exceed the immediate health beneﬁts. These irrecoverable treat-
ment costs are offset only by cost savings and health beneﬁts in
the longer run; that is, initially negative NHEs (losses) are only
gradually compensated by later positive ones (gains). Therefore, a
technology expected to be cost-effective may accumulate sufﬁcient
“gains” to compensate earlier “losses” only after some considerable
time. Whether this type of irrecoverable opportunity cost is signiﬁ-
cant (i.e., might inﬂuence decisions) depends on whether treatment
decisions for individual patients are irreversible, which, in part,
depends on the nature of the disease. For example, in an acute
condition, the decision to treat a particular patient with a technology
cannot be reconsidered at a later date, whereas for a chronic
condition the decision to treat can be delayed until the uncertainty
is resolved. Therefore, the commitment of irrecoverable opportunity
costs (negative NHE) can be avoided [21]. In these circumstances, OIR
or Reject avoids this commitment and preserves the option to
approve the technology at a later date when its purchase represents
a “less risky investment” [21].
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The presence of irrecoverable costs for a technology that is
expected to be cost-effective will inﬂuence guidance and be
regarded as “signiﬁcant” only if there are future events (research
reporting or other sources of uncertainty resolving) that might
change guidance. For example, if research is possible with appro-
val and is expected to be worthwhile, AWR does not necessarily
follow as previously (e.g., see AWR1 in Fig. 1) because the impact of
irrecoverable costs must also be considered. Now OIR may bemore
appropriate than AWR (e.g., the choice between OIR4 and AWR4 in
Fig. 2), even though the research would be possible with approval
because OIR avoids the commitment of irrecoverable costs until
the results of research are known. This is especially the case when
there are also other sources of uncertainty that might resolve
while the research is being conducted because it increases the
chance that guidance will be revised (e.g., OIR3 or AWR3 in Fig. 2).
If research is not possible with approval but is expected to be
worthwhile, then OIR will be appropriate if the opportunity costs of
early approval are judged to exceed the beneﬁts (e.g., OIR6 rather
than Approve9 in Fig. 2). Irrecoverable costs will tend to make OIR
rather than approval more likely, particularly when there are other
sources of uncertainty that might resolve while the research is being
conducted (e.g., OIR5 rather than Approve7 in Fig. 2).
If research is not judged worthwhile, approval does not
necessarily follow as previously (e.g., Approve1,3,4 in Fig. 1). Now
the technology should be approved only if there are no other
sources of uncertainty. If there are other sources of uncertainty,
then an assessment of the beneﬁts and costs of early approval
that takes account of irrecoverable costs and the risk that
guidance might change in the future is needed. Therefore, Reject
rather than approval is possible, even though a technology is
expected to be cost-effective, because the decision to commit the
irrecoverable costs can be reconsidered once the other sources of
uncertainty have resolved (e.g., Reject5,6 in Fig. 2).
Technologies not expected to be cost-effective
The presence of irrecoverable costs for technologies not expected to
be cost-effective means that Reject is more likely to be appropriate
than AWRwhen research is not possible without approval (see AWR5
in Fig. 3). This is because a decision to reject, although it may be
revised to approve, generally does not commit irrecoverable costs.
There may be circumstances when implementing guidance to reject
a technology also requires resources if it has already been diffused
into clinical practice. If these are signiﬁcant they should be taken into
account in the same way as other irrecoverable costs, tending to
make AWR more likely to be appropriate.
Changes in the Effective Price of a Technology
Any change in the effective price of the technology will affect the
key assessments, leading to different categories of guidance. For
example, OIR for a technology, which is expected to be cost-
effective, might be revised to Approve with a sufﬁcient price
reduction because the beneﬁts of early approval will be greater
and the value of additional evidence will tend to be lower (e.g.,
from OIR1 to Approve2 in Fig. 1). Similarly, AWR might be revised
to Approve if the beneﬁts of early approval now exceed the value
of additional evidence (e.g., from AWR1 to Approve2 in Fig. 1).
Therefore, consideration of the effect of price changes on OIR and
AWR is needed when assessing the potential impact of discount
schemes and more direct price negotiation [24].
Even if direct price negotiation is possible through a value-
based pricing scheme [10], it will be important to retain OIR and
AWR as possibilities because there is no guarantee that manu-
facturers will always agree to the lower price below which
Approve rather than OIR or AWR would be appropriate, and there
may be many circumstances when there is no effective pricereduction that would make Approve appropriate. For example,
Reject or OIR guidance may still be appropriate even if the
effective price of a technology was zero if there is substantial
uncertainty about its effectiveness and/or potential for harms.Discussion
Each sequence of assessment and decision leads to a different
category and type of guidance for technologies with differing
characteristics, indications, and target populations. The different
types of guidance illustrate how similar guidance might be arrived
at but in different ways, adding to the transparency of the appraisal
and helping to be explicit about the particular combination of
considerations that underpin the guidance. There are many circum-
stances when AWR and OIR are applicable. For example, there are
ﬁve types of OIR that may be appropriate when a technology is
expected to be cost-effective. Even when research is possible with
approval, OIR is appropriate if there are signiﬁcant irrecoverable
costs. Reject remains a possibility even for a cost-effective technology
if there are irrecoverable costs. Therefore, the full range of categories
of guidance (OIR and Reject as well as AWR and Approve) ought to be
considered for technologies that on the balance of existing evidence
and current prices are expected to be cost-effective. It is only
approval that can be ruled out if a technology is not expected to be
cost-effective; that is, cost-effectiveness is a necessary but not
sufﬁcient condition for approval but lack of cost-effectiveness is
neither necessary nor sufﬁcient for rejection. There are circum-
stances when AWR may be appropriate even when a technology is
not expected to be cost-effective. Importantly, the category of
guidance only partly depends on an assessment of expected cost-
effectiveness. A number of other key assessments are required: the
need for evidence; whether the type of research required is possible
with approval; the expected longer term beneﬁts and costs of
research that is likely to be conducted; the impact of other sources
of uncertainty that will resolve over time; and the signiﬁcance of any
irrecoverable costs.
This article has set out the key principles of what assessments
are needed for coverage decisions. It has not speciﬁed how these
assessments might be informed because this can differ across
different jurisdictions. The explicit framework for OIR and AWR
decisions is likely to have a number of implications for policy (e.
g., drug pricing and incentives for evaluative research), as well as
the process of appraisal (e.g., greater involvement of research
commissioners) and the methods of appraisal (e.g., additional
information, evidence, and analysis that might be required).
Coverage decisions that are based on some assessment of the
likely health opportunity costs, whether or not a “threshold” is
explicitly stated, sends a signal of how much health care systems
can afford to pay for the beneﬁts that new technologies offer.
Manufacturers inevitably respond to these incentives through their
pricing and investment decisions. Not only is price endogenous [28]
but the effects and the costs of developing and producing new
technologies are endogenous as well. Therefore, the role of reim-
bursement agencies can be seen as signaling collective demand for
the health beneﬁts that new technologies offer, reﬂecting the social
choices of howmuch resource is to bemade available for health care.
The endogeneity of price aligns the dynamic incentives for research
and development with the needs and resource constraints of health
care systems that reﬂect social values and mirror how temporary
monopolists with patent protection respond to demand in other
markets [29]. The principles of how the need for evidence might
inﬂuence coverage decisions and the implications that it has for
pricing decisions by manufacturers enables greater subtlety in the
signal sent and a better alignment of incentives for the development
of new technologies and evaluative research available to support
their use.
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